A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis

Anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease (MDA5(+) DM-ILD) is a life-threatening disease. This study aimed to develop a novel pulmonary CT visual scoring method for assessing the prognosis of the disease, and an artificial intelligence (AI) algorithm-based analysis and an idiopathic pulmonary fibrosis (IPF)-based scoring were conducted as comparators. A retrospective cohort of hospitalized patients with MDA5(+) DM-ILD was analyzed. Since most fatalities occur within the first half year of the disease course, the primary outcome was the six-month all-cause mortality since the time of admission. A ground glass opacity (GGO) and consolidation-weighted CT visual scoring model for MDA5(+) DM-ILD, namely 'MDA5 score', was then developed with C-index values of 0.80 (95%CI 0.75-0.86) in the derivation dataset (n = 116) and 0.84 (95%CI 0.71-0.97) in the validation dataset (n = 57), respectively. While, the AI algorithm-based analysis, namely 'AI score', yielded C-index 0.78 (95%CI 0.72-0.84) for the derivation dataset and 0.77 (95%CI 0.64-0.90) for the validation dataset. These findings suggest that the newly derived 'MDA5 score' may serve as an applicable prognostic predictor for MDA5(+) DM-ILD and facilitate further clinical trial design. The AI based CT quantitative analysis provided a promising solution for ILD evaluation.

Automated summary

An innovative CT visual scoring method and AI algorithm analysis were developed to assess the prognosis of MDA5(+) DM-ILD, showing promising results for clinical trial design. These findings provide a potential solution for ILD evaluation.